Editor’s Note: The home page of the BioNJ website provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to email their news releases to BioNJ.
November 29
Merck Provides Update on EU Marketing Authorization Application for Ridaforolimus
Merck Launches Maternal Health Awareness Campaign, Once Upon a Birth, with Actress Melissa Joan Hart
NPS Pharmaceuticals Announces Publication of Pivotal Phase 3 Study of Gattex® (teduglutide) in Short Bowel Syndrome-Intestinal Failure Patients
ThromboGenics’ Shares to Join the STOXX600 Index
ThromboGenics Lands Licensing Deal of the Year at SCRIP Awards 2012
November 28
Senesco to Present on SNS01-T at 54th American Society of Hematology Annual Meeting
Celgene Corporation to Webcast at an Upcoming Investor Conference and the 54th American Society of Hematology Annual Meeting
November 27
Targeted Medical Pharma Signs Agreement to Assign Certain Accounts Receivables to Cambridge Medical Funding Group
Arno Therapeutics Completes $12.7 Million Financing
NPS Pharmaceuticals to Present at Deutsche Bank BioFEST Conference
Merck Increases Quarterly Dividend
Merck and Endocyte Announce Acceptance for Review of European Marketing Authorization Applications for Vintafolide and Companion Diagnostic Etarfolatide for Folate-Receptor Positive Platinum-Resistant Ovarian Cancer
Bracco Diagnostics Inc. Issues Voluntary Nationwide Recall of Isovue® (iopamidol injection) Pre-Filled Power Injector Syringes due to Presence of Particulates
Unigene and Tarix Pharmaceuticals Enter Definitive Licensing Agreement for “Peptelligence-Engineered” Txa127
American CryoStem Corporation and XeoStem LLC Complete Adipose Stem Cell Processing and Tissue Banking Agreement
November 26
Senesco Technologies Provides Corporate Update
November 21
Senesco Announces Quotation of Common Stock on the Over-the-Counter Securities Market
November 20
Lexicon Pharmaceuticals to Present at the Piper Jaffray Annual Healthcare Conference
November 19
Senesco Announces Delisting of Common Stock from NYSE MKT LLC and Pending Transfer to an Over-the-Counter Securities Market
INCRAFT™ AAA Stent-Graft System One-Year Follow-Up Data Presented at 2012 Veith Symposium
November 16
Unigene to Announce Third Quarter 2012 Financial Results on November 20, 2012
November 15
Foster Wheeler Joint Venture with Three Streams Engineering Ltd. Awarded Contract for Canadian Oil Sands Project
NovaDel Reports Unaudited Financial Results for the Nine Months Ended September 30, 2012
Celldex Therapeutics Announces Positive Three-Year Survival Data for Rindopepimut Phase 2 Clinical Program
November 14
Photocure Presentation at Jefferies 2012 Global Healthcare Conference
Soligenix Reports Third Quarter 2012 Financial Results and Highlights Recent Accomplishments
ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Long-Term Efficacy and Safety in Adult Patients Co-Infected with HIV-1 and Hepatitis B and/or C in a Subgroup Analysis at 240 Weeks
Dendreon Appoints Lindsay Rocco to Lead Corporate Communications
Durata Therapeutics Relocating Corporate Headquarters to Chicago
Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes
Bristol-Myers Squibb Foundation’s Together on Diabetes™ Marks World Diabetes Day with Second Annual Report and Two New Grants in India
CorMedix: Final Closing of 2012 Financing
November 13
Antares Pharma Announces Positive Results from Final MTX Medi-Jet™ Clinical Study
New Data Demonstrate KRYSTEXXA®-Treated Refractory Chronic Gout Patients Experienced Significantly Improved Health-Related Quality of Life
Temptime Corporation Receives Grand Challenges Explorations Grant for
Groundbreaking Research in Global Health and Development
ADMA Biologics Reports 2012 Third Quarter Results
US Government OKs SAFE-BioPharma® as Trust Framework Provider
Lupus Patients Treated With Epratuzumab Report Improvements in Health-Related Quality Of Life
Oral Apremilast Achieves Statistical Significance for the Primary Endpoint of ACR20 in the First Phase III Study (PALACE-1) in Patients with Psoriatic Arthritis
November 12
Lexicon Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
Long-Term Efficacy and Safety Results of Epratuzumab in Lupus Presented at Rheumatology Conference
New Head-to-Head Patient Reported Outcomes Data for Orencia® SC (abatacept) vs. Humira® (adalimumab) Presented at the 2012 American College of Rheumatology Annual Scientific Meeting
Bristol-Myers Squibb’s Investigational Hepatitis C Compounds Lambda and Daclatasvir Plus Ribavirin Achieved SVR12 in 93 Percent of Genotype 1b Treatment-Naive Patients In Phase IIb Study
Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 Achieved SVR12 of 94% in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection in Phase II Trial
Cyclacel Reports Third Quarter 2012 Financial Results
New Data Published in Annals of the Rheumatic Diseases Confirm Long-Term Safety and Efficacy of KRYSTEXXA® for the Treatment of Refractory Chronic Gout
November 11
Merck Presents Early-Stage Interim Data for MK-3475, an Investigational Therapy for the Treatment of Advanced Melanoma
November 10
Interim Phase II Data of Merck’s Investigational MK-5172 in Combination Therapy in Chronic Hepatitis C Virus Genotype 1 Infection to be Presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Merck Reports New Phase III Analyses on Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy, Including Cirrhotic Patients
November 9
Cyclacel Pharmaceuticals to Announce Release of Third Quarter 2012 Financial Results
Immunomedics Named Edison Patent Award Winner in Biotechnology by Research & Development Council of New Jersey
Celldex Therapeutics Announces Upcoming Presentation at Lazard Capital Markets Healthcare Conference
Durata Therapeutics Reports Third Quarter 2012 Financial and Corporate Results
Arno Therapeutics Reports Progress in Development of Clinical Biomarkers to Support Treatment of Breast Cancer with Onapristone
Chiromics and Bristol-Myers Squibb Form Drug Discovery Strategic Alliance
Chiromics and GlaxoSmithKline Enter into Collaboration
ABRAXANE® Demonstrates Statistically Significant Improvement in Overall Survival for Patients with Advanced Pancreatic Cancer in Phase III Study
As Biotech Investments Continue to Decline, New Life Sciences Angel Group Launched in NYC
November 8
FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohn’s Disease
Antares Pharma to Present at the Jefferies 2012 Global Healthcare Conference
Enzon Announces Two Oral Presentations at the Symposium of Drug Delivery Systems in Nanjing, China
Bristol-Myers Squibb to Present New Investigational Data on Orencia® (abatacept) at the 2012 American College of Rheumatology Annual Scientific Meeting
Columbia Laboratories Reports Third Quarter 2012 Financial Results
Durata Therapeutics to Present at Credit Suisse 2012 Healthcare Conference
Global Life Sciences Hiring Demand Retreated 12.1% in Q3
Immunomedics Announces First Quarter Fiscal 2013 Results and Clinical Program Developments
Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
November 7
Cyclacel to Present at Lazard Healthcare Conference
NPS Pharmaceuticals to Present at Upcoming Healthcare Conferences
Aegerion Pharmaceuticals Announces Third Quarter 2012 Financial Results
Antares Pharma Reports Third Quarter 2012 Financial and Operating Results
Bristol-Myers Squibb Foundation Announces Centers of Excellence Conference to Share Insights from Asian-Pacific Community Groups on Viral Hepatitis Management in Honor of the 10-Year Anniversary of Delivering Hope™
Bristol-Myers Squibb to Present at Credit Suisse Healthcare Conference
Celgene Corporation to Webcast at Two Upcoming Investor Conferences and the American College of Rheumatology
November 6
Personalized Medicine Potential of Cyclacel’s Innovative and Diverse Oncology Pipeline Highlighted at NCRI Cancer Conference
PTC Therapeutics Appoints Geoffrey McDonough, M.D. to Board of Directors
NPS Pharmaceuticals to Report Third Quarter 2012 Financial Results
IMS Health to Issue Third-Quarter 2012 Financial Results on November 12, Conference Call for Note Holders Scheduled for November 16
Aegerion Pharmaceuticals Announces Presentation at Jefferies Global Healthcare Conference in London
November 5
Cyclacel Receives $1.9 Million Translational Medicine Grant Award From the UK Biomedical Catalyst to Advance Its CYC065 Targeted Drug for Leukemias
Immunomedics Reports Potential Product Advances at the 2012 Annual Meeting of the American Society of Hematology
FDA Designates Durata Therapeutics’ Dalbavancin a Qualified Infectious Disease Product (QIDP)
Celldex Announces Upcoming Data Presentation at the American Society of Hematology 54th Annual Meeting and Exposition
Amicus Therapeutics Announces Updated Results From Phase 2 Extension Study of Migalastat HCl for Fabry Disease
Amicus Therapeutics Announces Third Quarter 2012 Financial Results & Corporate Updates
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
LX4211 Phase 2b Results Presented at American Heart Association Annual Conference
Emergency Hypertensive Acute Heart Failure Study PRONTO Demonstrates Clevidipine Superior to Standard of Care
November 3
Skuldtech and AB Science Announce the Identification of New Predictive Markers for Pancreatic Cancer Survival Associated with Masitinib Treatment
November 2
Merck Will Initiate Interferon-Free Phase II Clinical Trials for MK-5172, an Investigational, Once-Daily, Oral Treatment for Chronic Hepatitis C Virus
Bristol-Myers Squibb and Pfizer Announce New Data on Stroke Prevention in Atrial Fibrillation to be Presented at American Heart Association 2012 Scientific Sessions
Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for its Novel, Dual Mechanism Compound, AR-13324, for the Treatment of Glaucoma
Aegerion Pharmaceuticals Announces Publication in the Lancet of Data From Its Pivotal Phase III Study of Lomitapide in Adult Patients with Homozygous Familial Hypercholesterolemia (HoFH)
Hypertensive Acute Heart Failure Study Results to Be Presented at American Heart Association Scientific Sessions 2012
November 1
Cyclacel Announces Publication of Phase 2 Results for Sapacitabine in Elderly AML Patients in the Lancet Oncology
Columbia Laboratories Expects Ongoing Email and Phone Outages into Next Week
Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related to Vioxx
Bristol-Myers Squibb Receives Positive Decision from National Institute of Health and Clinical Excellence (NICE) for YERVOY®(ipilimumab)
Portola, Bristol-Myers Squibb and Pfizer Sign Clinical Collaboration Agreement to Study ELIQUIS® and Portola’s Universal Factor Xa Inhibitor Antidote PRT4445
October 31
Advaxis Updates Phase 2 Cervical Cancer Trial Data
Advaxis Announces $11.4 Million in Financial Commitments
Enzon Reports Third Quarter 2012 Results
October 29
Celldex Therapeutics Makes Significant Advancements in the Field of Protein-Based Vaccine Development
October 26
Results Third Quarter and First Nine Months 2012
Presentation of Third Quarter and First Nine Months 2012 Results
Columbia Laboratories Confirms FDA Denies Watson’s Appeal Related to Prochieve NDA for the Prevention of Preterm Birth
October 25
Columbia Laboratories Receives Nasdaq Minimum Bid Price Non-compliance Letter
Celgene Reports Third Quarter 2012 Operating and Financial Results
Durata Therapeutics Completes Target Enrollment in Phase 3 DISCOVER 2 Clinical Trial Comparing Dalbavancin to Vancomycin and Linezolid in ABSSSI Patients
October 24
Positive Results from Phase 2b Study of Ophthotech’s Novel Anti-PDGF Combination Agent Fovista™ to Be Presented at AAO Retina Subspecialty Day
Ezose Sciences Forms Alliance with Fast Forward to Discover Biomarkers to Diagnose Multiple Sclerosis
October 23
Ipsen US Awards up to $300,000 for Dystonia Fellowship Grants in 2013
Presentation of the Third Quarter 2012 Report
Pomalidomide Demonstrated Significant Progression-Free Survival and Overall Survival Advantages in Phase III Study of Heavily Pre-Treated Myeloma Patients
Pinsonault Unveils Keynote Lineup for the Spring 2013 Managed Markets Summit
Merck Announces Results from New Phase III Study Amongst Women for Corifollitropin Alfa, an Investigational Fertility Treatment for Controlled Ovarian Stimulation
Bard Announces Third Quarter Results
Bard Acquires Neomend, Inc.
SAPPHIRE Worldwide Study Data Presented at TCT 2012
October 22
ViroStatics AV-HALT Phase 2a Study in HIV/AIDS Paper Published in PLoS ONE
NPS Pharmaceuticals Reports Characteristics of Patients Who Achieved Independence from Parenteral Support in STEPS 2 Study of Gattex® (teduglutide) in Adult Short Bowel Syndrome
STENTYS Self-Apposing® Stent Continues to Demonstrate Low Mortality at One Year in APPOSITION III Trial
PTC Therapeutics Receives $1 Million Grant Award from the National Institutes of Health (NIH) to Support Research for a Treatment for Dengue Fever
Amicus Therapeutics Achieves Target Enrollment in Second Phase 3 Fabry Monotherapy Study
October 19
Precision Spine™ Plans to Introduce Three New Products at North American Spine Society Meeting in Dallas
Aegerion Pharmaceuticals to Webcast Investor Event
October 18
Aerie Pharmaceuticals Appoints Richard J. Rubino as Chief Financial Officer
Lexicon Announces Pricing of Common Stock Offering
October 17
VICTRELIS® (boceprevir) Awarded 2012 Prix Galien USA Best Pharmaceutical Agent
Bristol-Myers Squibb’s YERVOY® (ipilimumab) Awarded Prestigious Prix Galien USA Prize for Best Biotechnology Product
Lexicon Announces Proposed Common Stock Offering
Trading of Common Stock of Aegerion Pharmaceuticals Halted Today
FDA Advisory Committee Recommends Approval of Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
October 16
NPS Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Gattex® New Drug Application for the Treatment of Adults with Short Bowel Syndrome
Bristol-Myers Squibb to Present New Data Demonstrating Company’s Continuing Commitment to Research and Development in Liver Disease at The American Association for the Study of Liver Diseases (AASLD) Annual Meeting
AB Science Confirms the Filing for the Marketing Authorization Application to the European Medicines Agency of Masitinib in the Treatment of Pancreatic Cancer
Fraunhofer and University of Delaware to Host Technology Summit
FDA Advisory Committee Unanimously Recommends Approval of Gattex® (teduglutide) for Adults with Short Bowel Syndrome (SBS)
Amicus Therapeutics Announces Data Presentations and Posters at Upcoming Scientific Meetings
Unigene’s Licensee, Tarsa Therapeutics, Reports Positive Clinical Data in Phase 2 Study of Oral Calcitonin for Prevention of Postmenopausal Osteoporosis
October 15
AiCuris and Merck Enter Exclusive Worldwide License Agreement for Investigational Portfolio Targeting Human Cytomegalovirus
New Data from REPLACE Study Show Initiation of Bone Remodeling for Natpara®-Treated Patients with Hypoparathyroidism
Celgene Corporation to Announce Third Quarter 2012 Results on October 25, 2012
Durata Therapeutics Names Allison Wey as Vice President, Investor Relations and Public Affairs
CircuLite® Announces Four Presentations at Transcatheter Cardiovascular Therapeutics Conference
STENTYS to Present One-Year Interim Results From APPOSITION III Study at TCT Conference
U.S. Food and Drug Administration Approves Labeling Update for BARACLUDE® (entecavir) (0.5 mg/1 mg Tablets) to Include Data on African Americans and Liver Transplant Recipients with Chronic Hepatitis B in Adult Patients
Unigene’s Oral Pth Program Featured at Asbmr 2012 Annual Meeting
Cyclacel’s Sapacitabine Nearly Doubles Expected Survival of Elderly Patients with MDS After Front-Line Therapy Failure
The Medicines Company to Announce Third Quarter 2012 Financial Results on Wednesday, October 24, 2012
October 13
Merck Researchers Present BMD Data from a Phase II Study of Odanacatib, Merck’s Investigational Cat-K Inhibitor for Post-Menopausal Osteoporosis
October 12
FDA Posts Briefing Documents for Advisory Committee Meeting Reviewing Gattex® (teduglutide) for Adult Short Bowel Syndrome
FDA Approves ABRAXANE® for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Updated Phase 2 Survival Data of Cyclacel’s Sapacitabine for MDS Presented at
the Eighth Annual Hematologic Malignancies 2012 Conference
Second Phase 2 Trial of Telotristat Etiprate Shows Positive Results in Carcinoid Syndrome
Lexicon Initiates Phase 3 Clinical Trial of Telotristat Etiprate in Patients with Carcinoid Syndrome
October 11
Medicare Ruling Concerns Hospital CEOs, but Better Reporting, New Antibiotic Technology Can Lower Cardiac Device Infection Rates
On World Sight Day, Merck and Partners Mark 25 Years of Successful Collaboration To Help Eliminate River Blindness
CorMedix Successfully Completes and Passes ISO 13485 Certification Audit
Amicus Therapeutics Announces Positive Pompe Program Updates
October 10
Bard Declares Quarterly Dividend
October 9
Merck to Move Global Headquarters Within New Jersey
Lexicon Initiates Phase 3 Clinical Trial of Telotristat Etiprate in Patients with Carcinoid Syndrome
Immunomedics Discovers Potential New Therapy for Graft-Versus-Host Disease
Antares Pharma Announces Closing of Public Offering of Common Stock
October 8
Celgene Corporation to Announce Third Quarter 2012 Results on October 25, 2012
October 4
The Medicines Company Discontinues Phase 2b Trial of MDCO-2010
October 3
Durata Therapeutics to Present at 11th Annual BIO Investor Forum
Hospitals, Healthcare Providers to Benefit from New Premier Agreements for Blood/Specimen Collection and Ancillary Products
Soligenix Announces Formation of Acute Radiation Syndrome Scientific Advisory Board
Antares Pharma Announces Pricing of Public Offering of Common Stock
Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement
October 2
Antares Pharma Receives Development Milestone Payment
Catalent Announces Global Alliance with PAREXEL to Streamline Clinical Trial Material Supply Chain Process
FierceMedicalDevices Names TYRX® as One of Its “Fierce 15” Medical Device and Diagnostic Companies of 2012
Antares Pharma Announces Proposed Public Offering of Common Stock
October 1
Hospitals, Healthcare Providers to Benefit from New Premier Agreements for Safety Phlebotomy
ELIQUIS® (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at Varying Risk for Stroke and Bleeding
Bristol-Myers Squibb to Announce Results for Third Quarter on October 24
Photocure to Exit Allumera Business
September 29
New Four- and Five-Year Survival Data for YERVOY®(ipilimumab) in Treatment-Naïve and Previously-Treated Metastatic Melanoma Presented at the ESMO 2012 Congress (European Society for Medical Oncology)
September 28
Soligenix Announces Presentation of OrbeShield™ Data at Annual Radiation Research Society Meeting
PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors
Bristol-Myers Squibb Appoints Frances Heller Senior Vice President, Business Development
September 26
Alitair Receives Notice of Patent Allowance from the USPTO for Safer Formulation of Benzonatate
STENTYS Launches New Stent-Delivery System to Facilitate Implantation in More Complex Vessel Anatomies
FDA Acknowledges Receipt of Resubmission of the ELIQUIS®(apixaban) New Drug Application to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation
September 25
Antares Pharma Announces Successful Results from Vibex MTX Actual Human Use Study
CorMedix: Initial Close on Financing and Extension Granted to Regain Compliance with NYSE Amex Listing Standards
Bristol-Myers Squibb Foundation Celebrates Hispanic Heritage Month
September 24
Savient Pharmaceuticals Names John P. Hamill Chief Financial Officer
September 21
ELIQUIS® (apixaban) Receives CHMP Positive Opinion for the Prevention of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation
Vanderbilt University and Bristol-Myers Squibb Sign Collaboration Agreement to Develop Novel Treatments for Parkinson’s Disease
Global Life Sciences Executive Search and Interim Management Specialist RSA Places Actinium Pharmaceuticals CEO
Agreement for Daratumumab Receives Antitrust Clearance
September 20
Pilot Study in Patients with Head and Neck Cancer Finds That Derma Sciences’ MEDIHONEY® Reduces Hospital Stays in the U.K.
Savient Announces Multiple Abstracts Related to KRYSTEXXA® in the Treatment of Refractory Chronic Gout to be Presented at the 2012 ACR/ARHP Annual Meeting
Aegerion Pharmaceuticals Observes First Annual FH Awareness Day
Unigene to Present at the 2012 Obesity Society’s 30th Annual Scientific Meeting
Agile Therapeutics to Present at CBI’s Forum on Phase II-III Clinical Study Optimization
September 19
Unigene and Tarix Pharmaceuticals Report Highly Increased Oral Bioavailability of “Peptelligence-Engineered” TXA127
Baxter and Onconova Announce European Licensing Agreement for Anti-Cancer Compound Rigosertib
CRI Lifetree Appoints Alicia Craig-Rodriguez and Jose Marcos to Leadership Team
Ten Pharmaceutical Companies Unite to Accelerate Development of New Medicines
Celgene Corporation Announces Pomalidomide Will Be Reviewed at FDA Advisory Committee
September 18
Senesco Technologies Reports Fiscal Year 2012 Financial Results
Bristol-Myers Squibb Announces Dividend
Earlier in 2012
Alfagene Bioscinces and IZEN BIO Sign MOU. Click here to read the press release.
